Patrick Hsu: A New DNA Editing Technology Reported In Science Magazine
Patrick Hsu, Co-Founder of Arc Institute, posted on LinkedIn:
”Today in Science Magazine, we report a new DNA editing technology to seamlessly write massive changes into the right place in the human genome.
The reason gene editing hasn’t transformed human health is that current gene editing technologies like CRISPR are very limited.
The problem with CRISPR is that it cuts up your DNA, and then hopes that unreliable cellular DNA repair will make the wanted edit.
famously called it genome vandalism. More precise versions of CRISPR only edit less than 100 bases – often only a single base. Therefore, it’s not suited to make large changes safely.
However, most diseases are not the result of mutations in one location. Instead, their causes are spread all across the 3 billion base pairs in the genome.
We found bridge RNAs in bacterial “jumping genes” that allow us to make safe and arbitrary changes (insert, cut out, or flip) to every nucleotide within (up to) a 1 million bp sequence in your DNA.
In the paper, we show that we can correct the disease-causing DNA repeats that cause Friedreich’s ataxia (which is a rare neurological disease). The same approach could be applied to Huntington’s and other repeat expansion disorders.
This work was a wonderful collaboration with my Arc Institute cofounder Silvana Konermann and led by the indefatigable Nicholas Perry, alongside our amazing bridge editing team: Liam Bartie, Dhruva Katrekar, Gabriel Gonzalez, Matthew Durrant, James Pai, Alison Fanton, Juliana Martins, Masahiro Hiraizumi, Chiara Ricci-Tam, and Hiroshi Nishimasu”
Read the full article here.
Title: Megabase-scale human genome rearrangement with programmable bridge recombinases
Authors: Nicholas T. Perry, Liam J. Bartie, Dhruva Katrekar, Gabriel A. Gonzalez, Matthew G. Durrant, James J. Pai, Alison Fanton, Juliana Q. Martins, Masahiro Hiraizumi, Chiara Ricci-Tam, Hiroshi Nishimasu, Silvana Konermann, Patrick D. Hsu
Stay updated with Hemostasis Today.
-
Jun 2, 2026, 14:26PNH and Thrombosis: From Pathogenesis to Complement Inhibition
-
Jun 2, 2026, 14:08Jose Manuel Soria: Can Transcriptomics Improve VTE Risk Prediction?
-
Jun 2, 2026, 14:04Complications of Antiphospholipid Syndrome – APS Awareness Month Day 1 – APS Foundation of America
-
Jun 2, 2026, 14:00Wasimuddin Abdullah: Not Every Hilar ‘Mass’ Is a Mass
-
Jun 2, 2026, 13:53Brian Casey: SNMMI26 Image of the Year Highlights Novel DVT Imaging Technique
-
Jun 2, 2026, 13:47Zain Khalpey: The Path From Atherosclerosis to Heart Attack
-
Jun 2, 2026, 13:20Diana Pérez Moreno: Analgesic Efficacy and Safety of Erector Spinae Plane Block After Sternotomy and MICS
-
Jun 2, 2026, 13:15Gian Marco Petroni: Regional Anesthesia and Sedation for Hip Fracture Repair in Complex Patients
-
Jun 2, 2026, 13:04Open-Conformation ADAMTS13 R1206K as a Next-Generation Therapeutic Candidate for TTP – JTH